Neurointerventional Devices Market Outlook:
Neurointerventional Devices Market size was valued at USD 3.9 billion in 2025 and is anticipated to reach USD 8.2 billion by the end of 2035, registering a CAGR of 7.8% during the forecast period, i.e., 2026-2035. In 2026, the industry size of neurointerventional devices is estimated at USD 4.2 billion.
The growth in the neurointerventional devices market is necessitated predominantly by the increased incidence of neurological disorders such as ischemic stroke and cerebral aneurysm. For instance, in April 2026, as per a report published by the National Institute of Health (NIH), stroke is a major public health challenge in the U.S., which has accounted for 1 in 6 cardiovascular deaths in 2021, with one occurring every 40 seconds and a related death every 3 minutes. The report also outlined that in a year, more than 795,000 citizens in the country experience a stroke, most being first-time events, and ischemic strokes make up 87% of cases. The financial toll reached a substantial USD 56.5 billion in a year, whereas more than half of survivors aged 65+ face lasting mobility limitations. For instance, in October 2024, using SCORE Opera angiography systems, Shimadzu Corporation created SMART Voice that increases the effectiveness of examinations and lessens the workload for medical professionals, thus positively contributing to the market’s growth.
Neurological Disorders Global Impact: Key Statistics on Prevalence, Deaths, and Disability 2021
|
Indicator |
Value |
Interpretation |
|
Population affected |
3.4 billion people |
43.1% of the global population |
|
Share of the global population |
43.1% |
1 in 3 people affected |
|
Deaths (2021) |
11.1 million deaths |
High mortality burden |
|
Neurological conditions studied |
37 conditions |
Expanded from the previous 15 |
|
Change in DALYs since 1990 |
+18% increase |
Growing global burden |
Source: ABF
Moreover, demographic shifts such as increased geriatric patient populations increase the prevalence of cerebrovascular disease and therefore increase the denominator of patients. For instance, the article published by the World Health Organization in October 2025 revealed that, by 2050, 80% of older people will live in low- and middle-income countries. In addition, the report outlined that there were more adults aged 60 and over than children under 5 years. Between 2015 and 2050, the proportion of the global population over 60 will nearly double, rising from 12% to 22%. In this context, the neurointerventional devices market is expected to grow steadily over the coming years, owing to an aging population, ongoing research and development initiatives, and technical advancements.
Key Neurointerventional Devices Market Insights Summary:
Regional Highlights:
- North America is projected to capture 37.4% share by 2035 in the neurointerventional devices market, underpinned by the high prevalence of vascular neurological disorders and rapid uptake of advanced thrombectomy technologies supported by sophisticated healthcare infrastructure
- Asia Pacific is expected to witness accelerated expansion during 2026-2035, buoyed by rising demand for affordable neurointerventional therapies, expanding middle-class populations, and improving access to specialist neurovascular care across urban centers
- The neurointerventional devices market in the U.S. accounts for almost 76.7% of the share in North America, which is driven by the continuous advancements in device technology and a stronger emphasis on early diagnosis and rapid clinical intervention.
Segment Insights:
- The stroke segment is forecast to account for 62.3% share by 2035 in the neurointerventional devices market, reinforced by escalating demand for next-generation thrombectomy devices, embolic protection technologies, and continuous innovation in neuroimaging solutions
- The hospital segment is anticipated to secure a lucrative share by 2035, attributed to advanced infrastructure capabilities, specialized neurointerventional facilities, and increasing patient volumes associated with neurological conditions
Key Growth Trends:
- Rising demand for minimally invasive procedures
- Surging R&D activities and funding
Major Challenges:
- Lack of skilled professionals
- Post-market surveillance
Key Players: Medtronic plc (Ireland),Stryker Corporation (U.S.),Johnson & Johnson (U.S.),Penumbra, Inc. (U.S.),Terumo Corporation (Japan),MicroVention Inc. (U.S.),Boston Scientific Corporation (U.S.),Abbott Laboratories (U.S.),Balt SAS (France),Acandis GmbH (Germany),Phenox GmbH (Germany),Rapid Medical Ltd. (Israel),Imperative Care, Inc. (U.S.),W. L. Gore & Associates (U.S.),Terumo Neuro (U.S.),Genentech (U.S.),Eisai Co., Ltd. (Japan),Merit Medical Systems, Inc. (U.S.),Integer Holdings Corporation (U.S.),Asahi Intecc Co., Ltd. (Japan),Kaneka Corporation (Japan),Nihon Kohden (Japan),Lepu Medical Technology (China),MicroPort Scientific Corporation (China).
Global Neurointerventional Devices Market Forecast and Regional Outlook:
Market Size & Growth Projections:
- 2025 Market Size: USD 3.9 billion
- 2026 Market Size: USD 4.2 billion
- Projected Market Size: USD 8.2 billion by 2035
- Growth Forecasts: 7.8% CAGR (2026-2035)
Key Regional Dynamics:
- Largest Region: North America (37.4% Share by 2035)
- Fastest Growing Region: Asia Pacific
- Dominating Countries: United States, Germany, Japan, China, Canada
- Emerging Countries: India, China, South Korea, Singapore, Australia
Last updated on : 8 June, 2026
Neurointerventional Devices Market - Growth Drivers and Challenges
Growth Drivers
- Rising demand for minimally invasive procedures: One of the main growth catalysts in the neurointerventional devices market is the rising demand for minimally invasive procedures. Through such processes, patients recover from the treatment faster, experience fewer complications, and leave fewer scars. To enable efficient and targeted therapy, companies are encouraging innovations such as micro-stents and high-end catheters. In February 2024, at #ECR2024, Philips presented Azurion neuro biplane system, specifically made to boost and enhance minimally invasive diagnosis and treatment for stroke and other neurovascular diseases. It possesses advanced 2D/3D imaging, flexible X-ray detector positioning, and AI-powered service monitoring, and the system streamlines workflows and boosts efficiency in angio suites, making it suitable for bolstering the market growth.
- Surging R&D activities and funding: The neurointerventional devices market is also witnessing a sharp growth graph which is being fueled by rising R&D activity and high investments. For instance, in April 2024, neuroClues announced that a new USD 5.2 million funding round was successfully closed. Its innovative eye-tracking technology promised to help diagnose neurodegenerative diseases earlier. In addition, the emerging R&D boom focuses on improving the efficiency of devices, rising patient outcomes, and enhancing conditions treatable through the services of devices for neurological disorders. Thus, developments in biomaterials, neuroimaging, and robots are being integrated intensely, allowing players to reap encouraging growth opportunities over the upcoming years.
Neurointerventional Devices Market Developments 2025: Company-Wise Product Launches, Technologies, and Growth Opportunities in Thrombectomy and Flow Diverter Categories
|
Company |
Development (Official Release) |
Device / Technology |
Clinical Focus Area |
Neurointerventional Devices Market Opportunity |
|
Medtronic |
First commercial use of Liberant™ thrombectomy system in the U.S. (Mount Sinai Hospital) |
Mechanical aspiration thrombectomy system |
Peripheral + vascular clot removal (adjacent to neurovascular thrombectomy segment) |
Expands aspiration thrombectomy portfolio |
|
Stryker Corporation (via Inari Medical) |
Launch of InThrill® Thrombectomy System (2025) |
Small-vessel & AV access thrombectomy device |
Rapid clot removal in small vessels |
Strengthens dominance in thrombectomy innovation |
|
Mentice |
FDA clearance & U.S. launch of Ankyras® 4.0 flow diverter planning platform |
Neurovascular simulation & planning software |
Intracranial aneurysm flow diverter planning |
Expands digital neurointerventional ecosystem |
Source: Company Official Press Releases
Challenges
- Lack of skilled professionals: The most extreme challenge in the neurointerventional devices market is the perpetual lack of highly qualified professionals. Neurointerventional procedures demand very high levels of training and clinical expertise, thus serving as a limitation to service delivery. Highly qualified practitioners are hence scarce and beyond reach for high-level care, particularly in rural settings. The shortage also serves as a limitation to the proper application of new technology and procedures, thus inhibiting market penetration and destroying the best patient outcomes. This deficit can be rectified through enhanced training programs and resource allocation to grow the market sustainably. As a result, healthcare providers need to face challenges in scaling neurointerventional services, which can delay procedure volumes and restrict market growth in underserved regions.
- Post-market surveillance: The inhibitor to the neurointerventional devices market is post-market surveillance. The design complexity of the devices and implantation into delicate neurological anatomy requires monitoring long-term performance and safety. Apart from this, the aspect of poor systematic follow-up of patients and data collection undermines maximal surveillance capability. Hence, the detection of unforeseen but serious side effects may endanger patients. Moreover, anatomical variability and device delivery technique make real-world device performance interpretation difficult. Hence, post-marketing monitoring by improved registries, effective reporting systems, and cross-stakeholder data sharing ensures ongoing safety and effectiveness of neurointerventional devices.
Neurointerventional Devices Market Size and Forecast:
| Report Attribute | Details |
|---|---|
|
Base Year |
2025 |
|
Forecast Year |
2026-2035 |
|
CAGR |
7.8% |
|
Base Year Market Size (2025) |
USD 3.9 billion |
|
Forecast Year Market Size (2035) |
USD 8.2 billion |
|
Regional Scope |
|
Neurointerventional Devices Market Segmentation:
Indication Segment Analysis
The stroke segment in the neurointerventional devices market is anticipated to dominate with 62.3% by the end of 2035. Acute presentation of ischemic stroke necessitates immediate re-establishment of cerebral perfusion, which in turn is fueling the demand for innovative thrombectomy devices as well as embolic protection devices. Therefore, next-generation clot retrieval devices and neuroimaging technologies are the uncompromising need to ensure maximal procedure efficacy and outcome. For instance, in April 2023, RapidAI announced that Rapid NCCT stroke, which is a device to detect suspected intracranial hemorrhage and large vessel occlusion from value-based CT imaging, had received FDA 510(k) clearance. This is a significant addition to RapidAI's suite of non-contrast-based solutions for stroke and trauma care. Hence, such constant innovations by the leading pioneers will position the subsegment for strong dominance over the years ahead.
Application Segment Analysis
Based on the application segment, the hospital segment is anticipated to garner a lucrative share by 2035, attributable to the state-of-the-art infrastructure and large patient care facilities. It includes advanced imaging modalities, specialized operating rooms, and intensive care units to manage complicated neurointerventional procedures. The hospitals are therefore the point of origin for managing such acute neurologic disorders, such as ischemic stroke and intracranial hemorrhage, with critical necessity. For instance, in March 2024, according to a study published in The Lancet Neurology, more than 3 billion people globally lived with a neurological condition in a year. The report also outlined that over the past four decades, there has been an 18% increase in the total number of neurological conditions, benefiting the overall neurointerventional devices market.
Product Segment Analysis
By the conclusion of the forecast period, the catheter segment is projected to attain a considerable share in the neurointerventional devices market. The segment’s growth is largely attributable to the increasing adoption of minimally invasive neurovascular procedures and continuous advancements in catheter technologies that enhance navigability, precision, and access to complex intracranial anatomies. In addition, the growing preference for endovascular treatments and the development of specialized aspiration and microcatheters are also supporting the segment’s expansion. In April 2024, Route 92 Medical received FDA 510(k) clearance for its FreeClimb 54 reperfusion system, pairing the FreeClimb 54 aspiration catheter with the Tenzing 5 delivery catheter, with a main goal to expand treatment options in endovascular thrombectomy. It is designed for rapid and predictable clot removal; the system’s robust design supports multiple passes and distal clot access when first-line therapies fall short.
Our in-depth analysis of the neurointerventional devices market includes the following segments:
|
Segment |
Subsegments |
|
Indication |
|
|
Application |
|
|
Product |
|
Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Neurointerventional Devices Market - Regional Analysis
North America Market Insights
The neurointerventional devices market in North America is expected to maintain its dominance during the forecast timeline, capturing the highest share of 37.4%. It is characterized by high growth, primarily spurred by the common prevalence of high vascular neurological disorders and the highly advanced healthcare infrastructure. Moreover, the rapid adoption of sophisticated thrombectomy devices in acute ischemic stroke due to a less regulated process, along with the widespread availability of stroke centers, fuels the market demand. As per an article published by NIH in November 2025, nervous system disorders affected 180.3 million citizens in the U.S. out of a population of 332.7 million, making them the leading cause of disability with 16.6 million DALYs. Besides, stroke contributed the highest disability burden, which is 3.9 million DALYs, followed by Alzheimer’s disease and dementias, 3.3 million, diabetic neuropathy, 2.2 million, and migraine, 2.1 million.
The successful clinical trials by companies in incorporating innovative devices to bring efficacy in neurological disorders are certain drivers boosting the U.S. neurointerventional devices market. In addition, the presence of a well-established healthcare infrastructure, favorable medical reimbursement policies, and expanding training programs for neurointerventional specialists across the country also support the widespread adoption of these life-saving technologies. For instance, in July 2024, Rapid Medical completed the first neurovascular cases in the U.S. following FDA approval of the active access solution. In case of peripheral vascular and neuro procedures, the DRIVEWIRETM 24's deflectable tip provides exceptional catheter and device navigation. Hence, such instances underscore the country's higher focus on advancing neurovascular care, thereby enhancing the overall procedural efficiency, improving patient outcomes, and solidifying the growth trajectory of the U.S. market.
The Canada neurointerventional devices market is poised to witness substantial growth during the forecast period, largely propelled by the supportive regulatory framework. The country’s market also benefits from a centralized healthcare system, which emphasizes the standardization of stroke care protocols and quick access to specialized neurological centers. For instance, in March 2023, the Minister of Health, Canada, announced a total of USD 38.3 million investment over five years for a new Brain Health and Cognitive Impairment in Aging (BHCIA) Research Initiative through the Canadian Institutes of Health Research (CIHR) Institute of Aging. The initiative seeks to enhance the care and services provided to individuals with cognitive impairment by creating and launching strategic funding opportunities. With such administrative support, the country is expected to witness unprecedented growth in the upcoming years, encouraging more players to establish their footprint in Canada market.
APAC Market Insights
The Asia Pacific neurointerventional devices market is predominantly driven by the demand for affordable neurointerventional therapies. In addition, the growth is spurred by the development of the burgeoning middle-class population and enhanced access to specialist neurovascular care in urban areas of the region. Meanwhile, indigenous production of neurointerventional devices at a fast speed with a cost-reduction focus, and accessibility of best-end care across the region are among the major growth trends. The developing healthcare infrastructure, continuously rising disposable incomes, and expanding medical insurance coverage across major economies such as China, Japan, and India are significantly boosting patient access to advanced treatments. In November 2024, Philips India introduced the new Azurion system, thereby showcasing advanced imaging capabilities with a main goal to streamline complex procedures across cardiology, neurology, vascular, and surgery. This system consists of enhanced C-arm rotation, rapid 2D-3D transitions, table-side controls, and AI-based uptime monitoring through the Philips Service Hub.
The strategic funding to foster innovative measures is the main factor driving the growth of the neurointerventional devices market in India. In addition, the swift expansion of private corporate hospital networks and specialized stroke centers into tier-2 and tier-3 cities is making advanced neurological care more accessible. In addition, growth is supported by increasing health insurance penetration, government initiatives which are aimed at upgrading tertiary healthcare infrastructure, and a growing influx of domestically manufactured medical devices. For instance, in December 2022, In-Med Prognostics announced to have raised USD 2.1 million, which was led by Exxora. These funds were utilized to stabilise and diversify the product portfolio and access global markets. It utilizes deep learning algorithms and machine learning to offer time-saving, correct neuro analysis, which helps in assessment and early diagnosis of neurological diseases such as dementia, alzheimer's, and parkinson's at reasonable costs.
The neurointerventional devices market in China is experiencing fast-paced growth owing to the robust growth in research and development, bolstering advancements and breakthroughs. Market expansion is strongly supported by explosive government healthcare initiatives, which are aimed at upgrading neurological care capabilities in provincial and county-level hospitals. This has led to a surge of high-quality, cost-competitive domestic alternatives challenging established international brands. For instance, in February 2025, China researchers found a new therapeutic target for Parkinson's disease and also identified a potentially promising small molecule drug. This discovery was made by researchers from Huashan Hospital under the Fudan University umbrella in Shanghai. Hence, the country is anticipated to attain phenomenal growth during the projected timeline.
Europe Market Insights
Europe neurointerventional devices market has acquired a prominent position, strongly supported by highly integrated healthcare systems and standardized clinical guidelines that prioritize immediate access to endovascular therapies. The regional market growth is characterized by strong collaborative research between academic medical centers and manufacturers, resulting in the rapid adoption of technologies such as sophisticated flow diverters, intrasaccular devices, and robotic-assisted neurovascular navigation systems. For instance, in June 2024, Penumbra announced the launch of BMX81 and BMX96 neuro access catheters in Europe, which are its most advanced offerings for managing ischemic and hemorrhagic stroke. It is built with laser-cut stainless steel hypotube technology, they provide superior stability, trackability, and larger inner diameters, thereby maintaining low outer diameters, enabling navigation through complex brain anatomy via femoral or radial access.
A highly sophisticated healthcare infrastructure and the extensive network of certified stroke units across major hospitals are responsibly boosting Germany neurointerventional devices market. The strong preference among the country’s clinicians for minimally invasive endovascular techniques is efficiently driving demand, as these procedures directly align with hospital efficiency goals by minimizing patient recovery times and shortening intensive care stays. For instance, in February 2026, Acandis GmbH began patient recruitment for the CARESTAR study, which is a randomized multicenter trial evaluating the CARESTO Heal Stent versus best medical therapy in symptomatic non-stenotic carotid disease, i.e., <50% stenosis. This study aims to address an unmet need by testing whether early endovascular stabilization of vulnerable carotid plaques can reduce recurrent embolic events and improve neurological outcomes.
The UK neurointerventional devices market development is highly supported by the National Health Service (NHS) and national clinical guidelines that prioritize the expansion of mechanical thrombectomy services and endovascular treatment networks across regional hyperacute stroke units. Apart from this, the market progression is sustained by collaboration between specialized neuroscience centers and global device manufacturers, which are facilitating the adoption of advanced flow diverters, remodeling balloons, and next-generation stent retrievers. As per an article published by North Bristol NHS Trust in May 2024, its stroke service has become the largest in the country, which was followed by major reconfiguration with 24/7 mechanical thrombectomy introduced in December 2022 and centralisation of urgent care at Southmead Hospital in May 2023. These changes enabled more than 400 thrombectomies in 2023, treating 200 more patients than the previous year, thus making it suitable for standard market growth.
Key Neurointerventional Devices Market Players:
- Medtronic plc (Ireland)
- Stryker Corporation (U.S.)
- Johnson & Johnson (U.S.)
- Penumbra, Inc. (U.S.)
- Terumo Corporation (Japan)
- MicroVention Inc. (U.S.)
- Boston Scientific Corporation (U.S.)
- Abbott Laboratories (U.S.)
- Balt SAS (France)
- Acandis GmbH (Germany)
- Phenox GmbH (Germany)
- Rapid Medical Ltd. (Israel)
- Imperative Care, Inc. (U.S.)
- W. L. Gore & Associates (U.S.)
- Terumo Neuro (U.S.)
- Genentech (U.S.)
- Eisai Co., Ltd. (Japan)
- Merit Medical Systems, Inc. (U.S.)
- Integer Holdings Corporation (U.S.)
- Asahi Intecc Co., Ltd. (Japan)
- Kaneka Corporation (Japan)
- Nihon Kohden (Japan)
- Lepu Medical Technology (China)
- MicroPort Scientific Corporation (China)
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Medtronic plc is one of the most influential players in the market, which has a strong portfolio that spans mechanical thrombectomy, stent retrievers, aspiration catheters, and neurovascular coils. The company’s Solitaire™ stent retriever system has become a widely adopted standard in acute ischemic stroke treatment across global stroke networks.
- Stryker Corporation is also a leading competitor in this landscape, and it is especially strong in ischemic stroke treatment technologies. Its Neurovascular division offers advanced stent retrievers such as Trevo™, aspiration systems, and balloon guide catheters, which are widely used in mechanical thrombectomy procedures.
- Johnson & Johnson is considered to be a foundational player that operates through its Cerenovus division, and it specializes in aneurysm and ischemic stroke technologies. Its portfolio includes Embotrap™ stent retrievers and cerebral aneurysm embolization coils designed for minimally invasive neurovascular procedures.
- Penumbra, Inc. is a major innovator in aspiration-based thrombectomy and neurovascular intervention technologies. The company is best known for its Penumbra System®, which uses continuous aspiration to remove clots in acute ischemic stroke patients.
- Terumo Corporation is based in Japan and offers a broad range of microcatheters, guidewires, coils, and embolization systems. The company supports complex endovascular procedures such as aneurysm coiling and embolization therapy, which have allowed it to maintain a strong position in the market.
Below is the list of some prominent players operating in the global neurointerventional devices market:
Corporate Landscape of the Neurointerventional Devices Market:
Recent Developments
- In July 2025, Stryker announced the launch of the surpass elite flow diverter in the U.S., South Korea, and Europe, unveiling its BioStealth Surface for enhanced thromboresistance and a redesigned implant with improved vessel-wall apposition.
- In July 2025, Terumo Neuro introduced new real-world physician preference data at SNIS 2025, thereby showing the SOFIA™ 88 catheter’s strong performance when compared to other super-bore catheters. In 105 procedures across 37 U.S. centers, 95% of physicians reported reliable target access.
- In March 2025, Genentech's TNKase thrombolytic received FDA approval for the treatment of acute ischemic stroke (AIS) in adults. TNKase is delivered as a single 5-second intravenous (IV) bolus, which is given as an IV bolus followed by a 60-minute infusion.
- In February 2025, Penumbra declared the release of the Access25 delivery microcatheter. It claims that Access25 is a single-lumen device that helps doctors reach the neurovasculature in order to administer Penumbra's 0.020-inch coil platform.
- In November 2024, EISAI and the National Center of Neurology and Psychology signed a research collaboration agreement to begin apolipoprotein E genetic testing in Japan's AD-DMT Registry.
- In September 2024, Nihon Kohden announced the purchase of a 71.4% share in NeuroAdvanced Corp. By fusing Ad-Tech's specialized intracranial electrodes with Nihon Kohden's well-established expertise in EEG systems, the company is better equipped to handle complex neurological conditions.
- Report ID: 7312
- Published Date: Jun 08, 2026
- Report Format: PDF, PPT
- Explore a preview of key market trends and insights
- Review sample data tables and segment breakdowns
- Experience the quality of our visual data representations
- Evaluate our report structure and research methodology
- Get a glimpse of competitive landscape analysis
- Understand how regional forecasts are presented
- Assess the depth of company profiling and benchmarking
- Preview how actionable insights can support your strategy
Explore real data and analysis
Frequently Asked Questions (FAQ)
Neurointerventional Devices Market Report Scope
Free Sample includes current and historical market size, growth trends, regional charts & tables, company profiles, segment-wise forecasts, and more.
Connect with our Expert
Copyright @ 2026 Research Nester. All Rights Reserved.
